Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Convalescent plasma therapy has been recognized as safe and plasma transfusion is routinely
used in clinical practice. A recent study showed that early administration of convalescent
plasma can decrease the risk of complications in specific high-risk population.
The aim of the present study is to offer convalescent plasma therapy to immunocompromised
patients and older adults in the early phase of a SARS-Cov-2 infection in order to accelerate
viral clearance and prevent complication
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Geneva
Collaborators:
Hôpital Fribourgeois Ospedale Regionale di Lugano University Hospital, Basel, Switzerland